CD4 and neoplasm: Collectively, our preclinical data, consistent with the clinical results, pointed to a critical contribution of CD4+ T cells associated with the MHCII upregulation on tumor cells and intratumoral immune cells to GBM control and patient survival after oHSV therapy.